Semaglutide / working resource

Clinical conversation planner

Bring specific questions and a source record to a qualified clinician.

Start with the product-specific question

Wegovy, Ozempic and Rybelsus

An accessible treatment-decision site with precise product distinctions. What should I know about wegovy, ozempic and rybelsus: product and indication map?

STEP1 randomized 1961 adults without diabetes to subcutaneous 2.4 mg semaglutide or placebo plus lifestyle support for 68 weeks.
Read the original record ↗

Open the Semaglutide library ↗

Choose the questions that need an answer.

Use the Semaglutide research to prepare a conversation, then let the clinician assess your individual situation. This worksheet does not determine eligibility or treatment.

What should I know about wegovy, ozempic and rybelsus: product and indication map?What should I know about oral versus injectable semaglutide evidence?What should I know about step trials: interpreting weight outcomes?Which evidence applies to the exact Semaglutide formulation being considered?What alternatives address the same goal, and what evidence supports them?Which risks, interactions and uncertainties matter for this decision?What would count as a useful outcome, and when would it be reassessed?Who should I contact if I have a problem or an unresolved question?The specific goal or uncertainty I want to discuss

Your conversation agenda

Select questions above to create your agenda here.

Source URLs and product documents to bringAnswers, unresolved points and agreed follow-up

Share personal health details only through your care provider's appropriate private channel. This page does not send or save your notes.

These fields stay in this page until you leave or reload. No notes are saved or transmitted. Print a copy if you want to keep your work. Educational organization tools do not replace clinical advice.

Explore all six resources ↗